Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Publikationen

Suchbegriffe: HER2, . Treffer: 52

2020

Bago-Horvath, Z; Rudas, M; Singer, CF; Greil, R; Balic, M; Lax, S; Kwasny, W; Hulla, W; Gnant, M; Filipits, M Predictive value of molecular subtypes in premenopausal women with hormone receptor-positive early breast cancer: Results from the ABCSG Trial 5.
Clin Cancer Res. 2020;
PubMed FullText FullText_MUG

 

Chen, Q; Yang, B; Nass, N; Schatz, C; Haybaeck, J Impact of Eukaryotic Translation Initiation Factors on Breast Cancer: Still Much to Investigate.
Cancers (Basel). 2020; 12(7):
PubMed FullText FullText_MUG

 

Dubsky, PC; Singer, CF; Egle, D; Wette, V; Petru, E; Balic, M; Pichler, A; Greil, R; Petzer, AL; Bago-Horvath, Z; Fesl, C; Meek, SM; Kronenwett, R; Rudas, M; Gnant, M; Filipits, M; Austrian Breast and Colorectal Cancer Study Group The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trial.
Eur J Cancer. 2020; 134:99-106
Web of Science PubMed FullText FullText_MUG

 

Fakler, F; Aykutlu, U; Brcic, L; Eidenhammer, S; Thueringer, A; Kashofer, K; Kulka, J; Timens, W; Popper, H Atypical goblet cell hyperplasia occurs in CPAM 1, 2, and 3, and is a probable precursor lesion for childhood adenocarcinoma.
Virchows Arch. 2020; 476(6):843-854
Web of Science PubMed FullText FullText_MUG

 

Huemer, F; Weiss, L; Regitnig, P; Winder, T; Hartmann, B; Thaler, J; Piringer, G; Schmitt, CA; Eisterer, W; Gänzer, H; Wüstner, A; Andel, J; Jagdt, B; Ulmer, H; Greil, R; Wöll, E Local and Central Evaluation of HER2 Positivity and Clinical Outcome in Advanced Gastric and Gastroesophageal Cancer-Results from the AGMT GASTRIC-5 Registry.
J Clin Med. 2020; 9(4): [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Jahn, SW; Bösl, A; Tsybrovskyy, O; Gruber-Rossipal, C; Helfgott, R; Fitzal, F; Knauer, M; Balic, M; Jasarevic, Z; Offner, F; Moinfar, F Clinically high-risk breast cancer displays markedly discordant molecular risk predictions between the MammaPrint and EndoPredict tests.
Br J Cancer. 2020; 20(1): [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Singer, CF; Pfeiler, G; Hubalek, M; Bartsch, R; Stöger, H; Pichler, A; Petru, E; Bjelic-Radisic, V; Greil, R; Rudas, M; Maria Tea, MK; Wette, V; Petzer, AL; Sevelda, P; Egle, D; Dubsky, PC; Filipits, M; Fitzal, F; Exner, R; Jakesz, R; Balic, M; Tinchon, C; Bago-Horvath, Z; Frantal, S; Gnant, M; Austrian Breast & Colorectal Cancer Study Group Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoadjuvant phase II study (ABCSG 34).
Eur J Cancer. 2020; 132:43-52
Web of Science PubMed FullText FullText_MUG

 

2019

Filipits, M; Dubsky, P; Rudas, M; Greil, R; Balic, M; Bago-Horvath, Z; Singer, CF; Hlauschek, D; Brown, K; Bernhisel, R; Kronenwett, R; Lancaster, JM; Fitzal, F; Gnant, M Prediction of Distant Recurrence Using EndoPredict Among Women with ER+, HER2(-) Node-Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only
CLIN CANCER RES. 2019; 25(13): 3865-3872. [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Müller, HD; Posch, F; Suppan, C; Bargfrieder, U; Gumpoldsberger, M; Hammer, R; Hauser, H; Dandachi, N; Prein, K; Stoeger, H; Lax, S; Balic, M Validation of Residual Cancer Burden as Prognostic Factor for Breast Cancer Patients After Neoadjuvant Therapy.
Ann Surg Oncol. 2019; 26(13):4274-4283 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Schmoeckel, E; Hofmann, S; Fromberger, D; Rottmann, M; Luthardt, B; Burges, A; Jeschke, U; Kirchner, T; Lax, SF; Mayr, D Comprehensive analysis of PD-L1 expression, HER2 amplification, ALK/EML4 fusion, and mismatch repair deficiency as putative predictive and prognostic factors in ovarian carcinoma.
Virchows Arch. 2019; 474(5):599-608
Web of Science PubMed FullText FullText_MUG

 

Suppan, C; Balic, M Adjuvant breast cancer: (neo)adjuvant therapy for HER2-positive breast cancer The best of ASCO 2019
MEMO-MAG EUR MED ONC. 2019; [OPEN ACCESS]
Web of Science FullText FullText_MUG

 

Veatch, JR; Jesernig, BL; Kargl, J; Fitzgibbon, M; Lee, SM; Baik, C; Martins, R; Houghton, AM; Riddell, SR Endogenous CD4+ T Cells Recognize Neoantigens in Lung Cancer Patients, Including Recurrent Oncogenic KRAS and ERBB2 (Her2) Driver Mutations.
CANCER IMMUNOL RES. 2019; 7(6): 910-922. [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Wöll, E; Eisterer, W; Gerger, A; Kühr, T; Prager, GW; Rumpold, H; Ulrich-Pur, H; Vogl, U; Winder, T; Weiss, L; Greil, R Treatment Algorithm for Patients With Gastric Adenocarcinoma: An Austrian Consensus on Systemic Therapy.
Anticancer Res. 2019; 39(9): 4589-4596. [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2018

Schochter, F; Rack, B; Tzschaschel, M; Polasik, A; Andergassen, U; Trapp, E; Alunni-Fabbroni, M; Schneeweiss, A; Müller, V; Pantel, K; Gade, J; Lorenz, R; Rezai, M; Tesch, H; Soeling, U; Fehm, T; Mahner, S; Schindlbeck, C; Lichtenegger, W; Beckmann, MW; Fasching, PA; Janni, W; Friedl, TWP; SUCCESS Study Group Endocrine Treatment with 2 Years of Tamoxifen versus 2 Years of Exemestane in Postmenopausal Patients with High-Risk Early Breast Cancer and Persisting Circulating Tumor Cells - First Results of the SUCCESS C Endocrine Treatment Sub-Study.
Oncol Res Treat. 2018; 41(3):93-98 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2017

Alduk, AM; Brcic, I; Podolski, P; Prutki, M Correlation of MRI features and pathohistological prognostic factors in invasive ductal breast carcinoma.
Acta Clin Belg. 2017; 72(5):306-312
Web of Science PubMed FullText FullText_MUG

 

Bayraktar, R; Pichler, M; Kanlikilicer, P; Ivan, C; Bayraktar, E; Kahraman, N; Aslan, B; Oguztuzun, S; Ulasli, M; Arslan, A; Calin, G; Lopez-Berestein, G; Ozpolat, B MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase.
Oncotarget. 2017; 8(7):11641-11658 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Loibner, M; Oberauner-Wappis, L; Viertler, C; Groelz, D; Zatloukal, K Protocol for HER2 FISH Using a Non-cross-linking, Formalin-free Tissue Fixative to Combine Advantages of Cryo-preservation and Formalin Fixation.
J Vis Exp. 2017; 8(130): [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Schramm, A; Schochter, F; Friedl, TWP; de Gregorio, N; Andergassen, U; Alunni-Fabbroni, M; Trapp, E; Jaeger, B; Heinrich, G; Camara, O; Decker, T; Ober, A; Mahner, S; Fehm, TN; Pantel, K; Fasching, PA; Schneeweiss, A; Janni, W; Rack, BK; SUCCESS Study Group Prevalence of Circulating Tumor Cells After Adjuvant Chemotherapy With or Without Anthracyclines in Patients With HER2-negative, Hormone Receptor-positive Early Breast Cancer.
Clin Breast Cancer. 2017; 17(4):279-285
Web of Science PubMed FullText FullText_MUG

 

Singer, CF; Tan, YY; Fitzal, F; Steger, GG; Egle, D; Reiner, A; Rudas, M; Moinfar, F; Gruber, C; Petru, E; Bartsch, R; Tendl, KA; Fuchs, D; Seifert, M; Exner, R; Balic, M; Bago-Horvath, Z; Filipits, M; Gnant, M; Austrian Breast and Colorectal Cancer Study Group Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast Cancer.
Clin Cancer Res. 2017; 23(14):3676-3683 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Suppan, C; Balic, M Early stage breast cancer treatment and prognostic factors: Post San Antonio Breast Cancer Symposium 2016.
Memo. 2017; 10(2):82-85 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2016

Czink, E; Heining, C; Weber, TF; Lasitschka, F; Schemmer, P; Schirmacher, P; Weiss, KH; Glimm, H; Brors, B; Weichert, W; Jäger, D; Fröhling, S; Springfeld, C [Durable remission under dual HER2 blockade with Trastuzumab and Pertuzumab in a patient with metastatic gallbladder cancer].
Z Gastroenterol. 2016; 54(5):426-430
Web of Science PubMed FullText FullText_MUG

 

Grillo, F; Fassan, M; Sarocchi, F; Fiocca, R; Mastracci, L HER2 heterogeneity in gastric/gastroesophageal cancers: From benchside to practice.
World J Gastroenterol. 2016; 22(26):5879-5887 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Jueckstock, J; Rack, B; Friedl, TW; Scholz, C; Steidl, J; Trapp, E; Tesch, H; Forstbauer, H; Lorenz, R; Rezai, M; Häberle, L; Alunni-Fabbroni, M; Schneeweiss, A; Beckmann, MW; Lichtenegger, W; Fasching, PA; Pantel, K; Janni, W; SUCCESS Study Group Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - Results of the German SUCCESS-A- trial.
BMC Cancer. 2016; 16(10):401-401 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

König, A; Vilsmaier, T; Rack, B; Friese, K; Janni, W; Jeschke, U; Andergassen, U; Trapp, E; Jückstock, J; Jäger, B; Alunni-Fabbroni, M; Friedl, T; Weissenbacher, T; SUCCESS STUDY GROUP Determination of Interleukin-4, -5, -6, -8 and -13 in Serum of Patients with Breast Cancer Before Treatment and its Correlation to Circulating Tumor Cells.
Anticancer Res. 2016; 36(6):3123-3130
Web of Science PubMed

 

Oberauner-Wappis, L; Loibner, M; Viertler, C; Groelz, D; Wyrich, R; Zatloukal, K Protocol for HER2 FISH determination on PAXgene-fixed and paraffin-embedded tissue in breast cancer.
Int J Exp Pathol. 2016; 97(2):202-206 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Rack, B; Jückstock, J; Trapp, E; Weissenbacher, T; Alunni-Fabbroni, M; Schramm, A; Widschwendter, P; Lato, K; Zwingers, T; Lorenz, R; Tesch, H; Schneeweiss, A; Fasching, P; Mahner, S; Beckmann, MW; Lichtenegger, W; Janni, W; SUCCESS Study Group CA27.29 as a tumour marker for risk evaluation and therapy monitoring in primary breast cancer patients.
Tumour Biol. 2016; 37(10):13769-13775
Web of Science PubMed FullText FullText_MUG

 

Rack, B; Zombirt, E; Trapp, E; Jückstock, J; Andergassen, U; Neugebauer, J; Kost, B; Weissenbacher, T; Jeschke, U; Schindlbeck, C; Janni, W; Alunni-Fabbroni, M Comparison of HER2 Expression in Primary Tumor and Disseminated Tumor Cells in the Bone Marrow of Breast Cancer Patients.
Oncology. 2016; 90(4):232-238 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Schneider, S; Thurnher, D; Kadletz, L; Seemann, R; Brunner, M; Kotowski, U; Schmid, R; Lill, C; Heiduschka, G Effects of neratinib and combination with irradiation and chemotherapy in head and neck cancer cells.
Oral Dis. 2016; 22(8):797-804
Web of Science PubMed FullText FullText_MUG

 

Schramm, A; Friedl, TW; Schochter, F; Scholz, C; de Gregorio, N; Huober, J; Rack, B; Trapp, E; Alunni-Fabbroni, M; Müller, V; Schneeweiss, A; Pantel, K; Meier-Stiegen, F; Hartkopf, A; Taran, FA; Wallwiener, D; Janni, W; Fehm, T Therapeutic intervention based on circulating tumor cell phenotype in metastatic breast cancer: concept of the DETECT study program.
Arch Gynecol Obstet. 2016; 293(2):271-281
Web of Science PubMed FullText FullText_MUG

 

2015

Benhaim, L; Zhang, W; Wakatsuki, T; Yang, D; Gerger, A; Bohanes, P; Paez, D; Loupakis, F; LaBonte, MJ; Ning, Y; El-Khoueiry, R; Ladner, R; Wilson, P; Zhang, H; Giamas, G; Stebbing, J; Lenz, HJ Genetic variants of kinase suppressors of Ras (KSR1) to predict survival in patients with ERα-positive advanced breast cancer.
Pharmacogenomics J. 2015; 15(3):235-240
Web of Science PubMed FullText FullText_MUG

 

Bollen, L; Wibmer, C; Wang, M; van der Linden, YM; Leithner, A; Bünger, CE; Jensen, AB; Fiocco, M; Bratschitsch, G; Pondaag, W; Bovée, JV; Dijkstra, PD Molecular phenotype is associated with survival in breast cancer patients with spinal bone metastases.
Clin Exp Metastasis. 2015; 32(1):1-5
Web of Science PubMed FullText FullText_MUG

 

Krenn-Pilko, S; Langsenlehner, U; Stojakovic, T; Pichler, M; Gerger, A; Kapp, KS; Langsenlehner, T An elevated preoperative plasma fibrinogen level is associated with poor disease-specific and overall survival in breast cancer patients.
Breast. 2015; 24(5):667-672
Web of Science PubMed FullText FullText_MUG

 

Pircher, M; Mlineritsch, B; Fridrik, MA; Dittrich, C; Lang, A; Petru, E; Weltermann, A; Thaler, J; Hufnagl, C; Gampenrieder, SP; Rinnerthaler, G; Ressler, S; Ulmer, H; Greil, R Lapatinib-plus-pegylated liposomal doxorubicin in advanced HER2-positive breast cancer following trastuzumab: a phase II trial.
Anticancer Res. 2015; 35(1):517-521
Web of Science PubMed

 

Widschwendter, P; Friedl, TW; Schwentner, L; DeGregorio, N; Jaeger, B; Schramm, A; Bekes, I; Deniz, M; Lato, K; Weissenbacher, T; Kost, B; Andergassen, U; Jueckstock, J; Neugebauer, J; Trapp, E; Fasching, PA; Beckmann, MW; Schneeweiss, A; Schrader, I; Rack, B; Janni, W; Scholz, C The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial.
Breast Cancer Res. 2015; 17(4):129-129 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2014

Cserni, G; Vörös, A; Liepniece-Karele, I; Bianchi, S; Vezzosi, V; Grabau, D; Sapino, A; Castellano, I; Regitnig, P; Foschini, MP; Zolota, V; Varga, Z; Figueiredo, P; Decker, T; Focke, C; Kulka, J; Kaya, H; Reiner-Concin, A; Amendoeira, I; Callagy, G; Caffrey, E; Wesseling, J; Wells, C Distribution pattern of the Ki67 labelling index in breast cancer and its implications for choosing cut-off values.
Breast. 2014; 23(3):259-263 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Gnant, M; Filipits, M; Greil, R; Stoeger, H; Rudas, M; Bago-Horvath, Z; Mlineritsch, B; Kwasny, W; Knauer, M; Singer, C; Jakesz, R; Dubsky, P; Fitzal, F; Bartsch, R; Steger, G; Balic, M; Ressler, S; Cowens, JW; Storhoff, J; Ferree, S; Schaper, C; Liu, S; Fesl, C; Nielsen, TO; Austrian Breast and Colorectal Cancer Study Group Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone.
Ann Oncol. 2014; 25(2):339-345 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Puzovic, V; Brcic, I; Ranogajec, I; Jakic-Razumovic, J Prognostic values of ETS-1, MMP-2 and MMP-9 expression and co-expression in breast cancer patients.
Neoplasma. 2014; 61(4): 439-446. [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Steger, GG; Greil, R; Lang, A; Rudas, M; Fitzal, F; Mlineritsch, B; Hartmann, BL; Bartsch, R; Melbinger, E; Hubalek, M; Stoeger, H; Dubsky, P; Ressler, S; Petzer, AL; Singer, CF; Muss, C; Jakesz, R; Gampenrieder, SP; Zielinski, CC; Fesl, C; Gnant, M Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24)
ANN ONCOL. 2014; 25(2): 366-371. [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2012

Lavasani, MA; Moinfar, F Molecular classification of breast carcinomas with particular emphasis on "basal-like" carcinoma: a critical review.
J Biophotonics. 2012; 5(4):345-366 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2010

Idris, T; Krippl, P; Lang, U; Petru, E Long-Term Disease Control with Lapatinib and Capecitabine in a Heavily Pretreated Patient with ErbB2-Positive Metastatic Breast Cancer.
Breast Care (Basel). 2010; 5(5):335-337 (- Case Report) [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2009

Kramer, A; Gattenlohner, S; Neben, K CUP syndrome: molecular pathogenesis and biology
Pathologe. 2009; 30(2):117-124
Web of Science PubMed FullText FullText_MUG

 

Reim, F; Dombrowski, Y; Ritter, C; Buttmann, M; Hausler, S; Ossadnik, M; Krockenberger, M; Beier, D; Beier, CP; Dietl, J; Becker, JC; Honig, A; Wischhusen, J Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: selective escape of CD44high/CD24low/HER2low breast cancer stem cells.
Cancer Res. 2009; 69(20):8058-8066 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

2008

Mlineritsch, B; Tausch, C; Singer, C; Luschin-Ebengreuth, G; Jakesz, R; Ploner, F; Stierer, M; Melbinger, E; Menzel, C; Urbania, A; Fridrik, M; Steger, G; Wohlmuth, P; Gnant, M; Greil, R; on behalf of the Austrian Breast, Colorectal Cancer Study Group (ABCSG) Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17).
Breast Cancer Res Treat. 2008; 112(1): 203-213.
Web of Science PubMed FullText FullText_MUG

 

Welter, S; Jacobs, J; Krbek, T; Tötsch, M; Stamatis, G Pulmonary metastases of breast cancer. When is resection indicated?
Eur J Cardiothorac Surg. 2008; 34(6):1228-1234 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2005

Bossuyt, V; Fadare, O; Martel, M; Ocal, IT; Burtness, B; Moinfar, F; Leibl, S; Tavassoli, FA Remarkably high frequency of EGFR expression in breast carcinomas with squamous differentiation.
Int J Surg Pathol. 2005; 13(4):319-327
Web of Science PubMed FullText FullText_MUG

 

Leithner, A; Gapp, M; Radl, R; Pascher, A; Krippl, P; Leithner, K; Windhager, R; Beham, A Immunohistochemical analysis of desmoid tumours.
J CLIN PATHOL. 2005; 58(11): 1152-1156. [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Liegl, B; Horn, LC; Moinfar, F Androgen receptors are frequently expressed in mammary and extramammary Paget's disease.
Mod Pathol. 2005; 18(10):1283-1288 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Reich, O; Liegl, B; Tamussino, K; Regauer, S p185HER2 overexpression and HER2 oncogene amplification in recurrent vulvar Paget's disease.
Mod Pathol. 2005; 18(3):354-357 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2004

Dandachi, N; Dietze, O; Hauser-Kronberger, C Evaluation of the clinical significance of HER2 amplification by chromogenic in situ hybridisation in patients with primary breast cancer.
ANTICANCER RES. 2004; 24: 2401-2406. [OPEN ACCESS]
Web of Science PubMed FullText

 

Hauser-Kronberger, C; Dandachi, N Comparison of chromogenic in situ hybridization with other methodologies for HER2 status assessment in breast cancer.
J MOL HISTOL. 2004; 35: 647-653.
Web of Science PubMed FullText FullText_MUG

 

Weitere 50 Treffer anzeigen
© Med Uni Graz Impressum